Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyIdentification
- Name
- Mometasone
- Accession Number
- DB00764 (APRD00289)
- Type
- Small Molecule
- Groups
- Approved, Vet approved
- Description
Mometasone is a medium-potency synthetic corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. Studies in asthmatic patients have demonstrated that mometasone provides a favorable ratio of topical to systemic activity due to its primary local effect along with the extensive hepatic metabolism and the lack of active metabolites. Though effective for the treatment of asthma, glucocorticoids do not affect asthma symptoms immediately. Maximum improvement in symptoms following inhaled administration of mometasone furoate may not be achieved for 1 to 2 weeks or longer after starting treatment. The anti-inflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes.
- Structure
Structure for DB00764 (Mometasone)
- Synonyms
- (+)-Mometasone
- Mometason
- Mometasona
- Mométasone
- Mometasonum
- External IDs
- LAS-41002 / LAS41002
- Product Ingredients
Ingredient UNII CAS InChI Key Mometasone furoate 04201GDN4R 83919-23-7 WOFMFGQZHJDGCX-ZULDAHANSA-N Mometasone furoate monohydrate MTW0WEG809 141646-00-6 AQCCVUHZMIMSIB-HRVPQZBTSA-N - Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Asmanex Inhalant 220 ug/1 Respiratory (inhalation) Physicians Total Care, Inc. 2006-03-09 Not applicable US 
Asmanex Inhalant 110 ug/1 Respiratory (inhalation) Merck Sharp & Dohme Limited 2005-03-30 Not applicable US Asmanex Inhalant 220 ug/1 Respiratory (inhalation) Merck Sharp & Dohme Limited 2005-03-30 Not applicable US Asmanex HFA Aerosol 200 ug/1 Respiratory (inhalation) Merck Sharp & Dohme Limited 2014-04-25 Not applicable US Asmanex HFA Aerosol 100 ug/1 Respiratory (inhalation) Merck Sharp & Dohme Limited 2014-04-25 Not applicable US Asmanex Twisthaler Powder 200 mcg Respiratory (inhalation) Merck Ltd. 2011-12-21 Not applicable Canada 
Asmanex Twisthaler Powder 100 mcg Respiratory (inhalation) Merck Ltd. 2015-04-08 Not applicable Canada Asmanex Twisthaler Powder 400 mcg Respiratory (inhalation) Merck Ltd. 2011-12-21 Not applicable Canada Elocom Cream Cream 0.1 % Topical Merck Ltd. 1991-12-31 Not applicable Canada Elocom Lotion Lotion 0.1 % Topical Merck Ltd. 1991-12-31 Not applicable Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Apo-mometasone Spray, metered 50 mcg Nasal Apotex Corporation 2013-03-25 Not applicable Canada Mometasone Furoate Ointment 1 mg/g Topical Rebel Distributors 2006-10-18 Not applicable US Mometasone Furoate Lotion 1 mg/g Topical Impax Generics 2007-11-21 2017-07-06 US Mometasone Furoate Cream 1 mg/g Topical Proficient Rx LP 2008-05-28 Not applicable US Mometasone Furoate Cream 1 mg/g Topical Clinical Solutions Wholsesale 2005-11-28 2017-06-24 US Mometasone Furoate Solution 1 mg/mL Topical Perrigo New York Inc. 2008-12-11 Not applicable US Mometasone Furoate Cream 1 mg/g Topical Glenmark Pharmaceuticals Inc.,Usa 2008-05-28 Not applicable US Mometasone Furoate Cream 1 mg/g Topical Gw Pharmaceuticals Ltd. 2006-08-23 Not applicable US Mometasone Furoate Ointment 1 mg/g Topical Remedy Repack 2017-01-25 Not applicable US Mometasone Furoate Cream 1 mg/g Topical E. Fougera & CO., A division of Fougera Pharmaceuticals Inc. 2005-04-08 Not applicable US - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Mosaspray Spray, metered 50 mcg Nasal Sandoz Canada Incorporated Not applicable Not applicable Canada Nasal Allergy and Congestion Relief Spray, metered 50 mcg Nasal Apotex Corporation Not applicable Not applicable Canada Nasonex Allergy and Congestion Spray, metered 50 mcg Nasal Merck Ltd. Not applicable Not applicable Canada - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Dulera Mometasone furoate (200 ug/1) + Formoterol fumarate (5 ug/1) Aerosol Respiratory (inhalation) A S Medication Solutions 2010-06-22 2017-06-20 US Dulera Mometasone furoate (100 ug/1) + Formoterol fumarate (5 ug/1) Aerosol Respiratory (inhalation) Merck Sharp & Dohme Limited 2010-06-22 Not applicable US Dulera Mometasone furoate (200 ug/1) + Formoterol fumarate (5 ug/1) Aerosol Respiratory (inhalation) Merck Sharp & Dohme Limited 2010-06-22 Not applicable US Zenhale Mometasone furoate (50 mcg) + Formoterol fumarate (5 mcg) Aerosol, metered Respiratory (inhalation) Merck Ltd. 2011-06-20 Not applicable Canada Zenhale Mometasone furoate (200 mcg) + Formoterol fumarate (5 mcg) Aerosol, metered Respiratory (inhalation) Merck Ltd. 2011-06-17 Not applicable Canada Zenhale Mometasone furoate (100 mcg) + Formoterol fumarate (5 mcg) Aerosol, metered Respiratory (inhalation) Merck Ltd. 2011-03-10 Not applicable Canada - International/Other Brands
- Ecural (Essex pharma) / Elocom (Merck) / Elomet (Schering-Plough) / Eziwin (Intas) / mometAid (Progreś Laboratories) / Novasone (Schering-Plough)
- Categories
- Adrenal Cortex Hormones
- Adrenals
- Agents to Treat Airway Disease
- Anti-Allergic Agents
- Anti-Inflammatory Agents
- Corticosteroids, Dermatological Preparations
- Corticosteroids, Plain
- Corticosteroids, Potent (Group III)
- Cytochrome P-450 CYP2C8 Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Dermatologic Agents
- Dermatologicals
- Pregnadienediols
- Pregnadienes
- Pregnanes
- Steroids
- UNII
- 8HR4QJ6DW8
- CAS number
- 105102-22-5
- Weight
- Average: 427.361
Monoisotopic: 426.136464798 - Chemical Formula
- C22H28Cl2O4
- InChI Key
- QLIIKPVHVRXHRI-CXSFZGCWSA-N
- InChI
- InChI=1S/C22H28Cl2O4/c1-12-8-16-15-5-4-13-9-14(25)6-7-19(13,2)21(15,24)17(26)10-20(16,3)22(12,28)18(27)11-23/h6-7,9,12,15-17,26,28H,4-5,8,10-11H2,1-3H3/t12-,15+,16+,17+,19+,20+,21+,22+/m1/s1
- IUPAC Name
- (1R,2S,10S,11S,13R,14R,15S,17S)-1-chloro-14-(2-chloroacetyl)-14,17-dihydroxy-2,13,15-trimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
- SMILES
- [H][[email protected]@]12C[[email protected]@H](C)[[email protected]](O)(C(=O)CCl)[[email protected]@]1(C)C[[email protected]](O)[[email protected]@]1(Cl)[[email protected]@]2([H])CCC2=CC(=O)C=C[[email protected]]12C
Pharmacology
- Indication
The inhaler is indicated for the maintenance treatment of asthma as prophylactic therapy. The nasal spray is indicated for the treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis.
- Structured Indications
- Pharmacodynamics
Mometasone is a medium-potency synthetic corticosteroid with antiinflammatory, antipruritic, and vasoconstrictive properties. Studies in asthmatic patients have demonstrated that mometasone provides a favorable ratio of topical to systemic activity due to its primary local effect along with the extensive hepatic metabolism and the lack of active metabolites. Though effective for the treatment of asthma, glucocorticoids do not affect asthma symptoms immediately. Maximum improvement in symptoms following inhaled administration of mometasone furoate may not be achieved for 1 to 2 weeks or longer after starting treatment. When glucocorticoids are discontinued, asthma stability may persist for several days or longer. Mometasone has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor which is approximately 12 times that of dexamethasone, 7 times that of triamcinolone acetonide, 5 times that of budesonide, and 1.5 times that of fluticasone. The clinical significance of these findings is unknown.
- Mechanism of action
Unbound corticosteroids cross cell membranes and bind with high affinity to specific cytoplasmic receptors. Inflammation is decreased by diminishing the release of leukocytic acid hydrolases, prevention of macrophage accumulation at inflamed sites, interference with leukocyte adhesion to the capillary wall, reduction of capillary membrane permeability, reduction of complement components, inhibition of histamine and kinin release, and interference with the formation of scar tissue. The antiinflammatory actions of corticosteroids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Mometasone furoate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor which is approximately 12 times that of dexamethasone, 7 times that of triamcinolone acetonide, 5 times that of budesonide, and 1.5 times that of fluticasone.
Target Actions Organism AGlucocorticoid receptor agonistHuman UProgesterone receptor agonistHuman - Absorption
Nasal spray is virtually undetectable in plasma
- Volume of distribution
- Not Available
- Protein binding
98% to 99% (in a concentration range of 5 to 500 ng/mL).
- Metabolism
Hepatic. Extensive metabolism to multiple metabolites. There are no major metabolites detectable in plasma. Upon in vitro incubation, one of the minor metabolites formed is 6ß-hydroxy-mometasone furoate. In human liver microsomes, the formation of the metabolite is regulated by cytochrome P-450 3A4.
- Route of elimination
- Not Available
- Half life
5.8 hours
- Clearance
- Not Available
- Toxicity
The potential for acute toxic effects following overdose with the mometasone inhaler is low. However, habitual overuse of the product can cause symptoms of steroid overload, including menstrual irregularities, acne, obesity, and muscle weakness. Single oral doses up to 8000 µg have been studied on human volunteers with no adverse events reported.
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (4R)-limonene The risk or severity of adverse effects can be increased when (4R)-limonene is combined with Mometasone. Investigational 1,10-Phenanthroline The risk or severity of adverse effects can be increased when Mometasone is combined with 1,10-Phenanthroline. Experimental Aceclofenac The risk or severity of adverse effects can be increased when Aceclofenac is combined with Mometasone. Approved, Investigational Acemetacin The risk or severity of adverse effects can be increased when Acemetacin is combined with Mometasone. Approved, Experimental, Investigational Acetylsalicylic acid The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Mometasone. Approved, Vet Approved Adapalene The risk or severity of adverse effects can be increased when Adapalene is combined with Mometasone. Approved Alclofenac The risk or severity of adverse effects can be increased when Alclofenac is combined with Mometasone. Approved, Withdrawn Aldesleukin Mometasone may decrease the antineoplastic activities of Aldesleukin. Approved Almasilate The bioavailability of Mometasone can be decreased when combined with Almasilate. Approved, Experimental Alminoprofen The risk or severity of adverse effects can be increased when Alminoprofen is combined with Mometasone. Experimental Aloglutamol The bioavailability of Mometasone can be decreased when combined with Aloglutamol. Approved Aloxiprin The risk or severity of adverse effects can be increased when Aloxiprin is combined with Mometasone. Experimental Aluminium The bioavailability of Mometasone can be decreased when combined with Aluminium. Approved, Investigational Aluminium acetoacetate The bioavailability of Mometasone can be decreased when combined with Aluminium acetoacetate. Experimental Aluminium glycinate The bioavailability of Mometasone can be decreased when combined with Aluminium glycinate. Experimental Aluminum hydroxide The bioavailability of Mometasone can be decreased when combined with Aluminum hydroxide. Approved, Investigational Ambenonium The risk or severity of adverse effects can be increased when Mometasone is combined with Ambenonium. Approved Aminosalicylic Acid The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Mometasone. Approved Amiodarone The serum concentration of Mometasone can be increased when it is combined with Amiodarone. Approved, Investigational Amodiaquine The serum concentration of Amodiaquine can be increased when it is combined with Mometasone. Approved, Investigational Amoxapine The therapeutic efficacy of Mometasone can be decreased when used in combination with Amoxapine. Approved Amphotericin B Mometasone may increase the hypokalemic activities of Amphotericin B. Approved, Investigational Andrographolide The risk or severity of adverse effects can be increased when Andrographolide is combined with Mometasone. Investigational Anisodamine The risk or severity of adverse effects can be increased when Anisodamine is combined with Mometasone. Investigational Anthrax immune globulin human The risk or severity of adverse effects can be increased when Mometasone is combined with Anthrax immune globulin human. Approved Antipyrine The risk or severity of adverse effects can be increased when Antipyrine is combined with Mometasone. Approved, Investigational Apalutamide The serum concentration of Mometasone can be decreased when it is combined with Apalutamide. Approved, Investigational Apocynin The risk or severity of adverse effects can be increased when Apocynin is combined with Mometasone. Investigational Apremilast The risk or severity of adverse effects can be increased when Apremilast is combined with Mometasone. Approved, Investigational Aprepitant The serum concentration of Mometasone can be increased when it is combined with Aprepitant. Approved, Investigational Atazanavir The serum concentration of Mometasone can be increased when it is combined with Atazanavir. Approved, Investigational Atracurium besylate Atracurium besylate may increase the adverse neuromuscular activities of Mometasone. Approved Azapropazone The risk or severity of adverse effects can be increased when Azapropazone is combined with Mometasone. Withdrawn Azelastine The risk or severity of adverse effects can be increased when Azelastine is combined with Mometasone. Approved Azosemide Mometasone may increase the hypokalemic activities of Azosemide. Investigational Bacillus calmette-guerin substrain connaught live antigen The risk or severity of adverse effects can be increased when Mometasone is combined with Bacillus calmette-guerin substrain connaught live antigen. Approved, Investigational Bacillus calmette-guerin substrain tice live antigen The risk or severity of adverse effects can be increased when Mometasone is combined with Bacillus calmette-guerin substrain tice live antigen. Approved Balsalazide The risk or severity of adverse effects can be increased when Balsalazide is combined with Mometasone. Approved, Investigational BCG vaccine The risk or severity of adverse effects can be increased when Mometasone is combined with BCG vaccine. Investigational Bendazac The risk or severity of adverse effects can be increased when Bendazac is combined with Mometasone. Experimental Bendroflumethiazide Mometasone may increase the hypokalemic activities of Bendroflumethiazide. Approved Benorilate The risk or severity of adverse effects can be increased when Benorilate is combined with Mometasone. Experimental Benoxaprofen The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Mometasone. Withdrawn Benzoic Acid The therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Mometasone. Approved, Investigational Benzydamine The risk or severity of adverse effects can be increased when Benzydamine is combined with Mometasone. Approved Bevonium The risk or severity of adverse effects can be increased when Bevonium is combined with Mometasone. Experimental Bismuth Subcitrate The bioavailability of Mometasone can be decreased when combined with Bismuth Subcitrate. Approved, Investigational Bismuth subnitrate The bioavailability of Mometasone can be decreased when combined with Bismuth subnitrate. Approved Boceprevir The serum concentration of Mometasone can be increased when it is combined with Boceprevir. Approved, Withdrawn Bromfenac The risk or severity of adverse effects can be increased when Bromfenac is combined with Mometasone. Approved Bucillamine The risk or severity of adverse effects can be increased when Bucillamine is combined with Mometasone. Investigational Bufexamac The risk or severity of adverse effects can be increased when Bufexamac is combined with Mometasone. Approved, Experimental Bumadizone The risk or severity of adverse effects can be increased when Bumadizone is combined with Mometasone. Experimental Bumetanide Mometasone may increase the hypokalemic activities of Bumetanide. Approved Calcitriol The therapeutic efficacy of Calcitriol can be decreased when used in combination with Mometasone. Approved, Nutraceutical Calcium Carbonate The bioavailability of Mometasone can be decreased when combined with Calcium Carbonate. Approved, Investigational Calcium silicate The bioavailability of Mometasone can be decreased when combined with Calcium silicate. Experimental Capromab pendetide Mometasone may decrease effectiveness of Capromab pendetide as a diagnostic agent. Approved Carbamazepine The serum concentration of Mometasone can be decreased when it is combined with Carbamazepine. Approved, Investigational Carbaspirin calcium The risk or severity of adverse effects can be increased when Carbaspirin calcium is combined with Mometasone. Experimental, Investigational Carprofen The risk or severity of adverse effects can be increased when Carprofen is combined with Mometasone. Approved, Vet Approved, Withdrawn Castanospermine The risk or severity of adverse effects can be increased when Castanospermine is combined with Mometasone. Experimental Celecoxib The risk or severity of adverse effects can be increased when Celecoxib is combined with Mometasone. Approved, Investigational Ceritinib Mometasone may increase the hyperglycemic activities of Ceritinib. Approved Chloroquine The risk or severity of adverse effects can be increased when Chloroquine is combined with Mometasone. Approved, Investigational, Vet Approved Chlorothiazide Mometasone may increase the hypokalemic activities of Chlorothiazide. Approved, Vet Approved Chlorotrianisene The serum concentration of Mometasone can be increased when it is combined with Chlorotrianisene. Investigational, Withdrawn Chlorthalidone Mometasone may increase the hypokalemic activities of Chlorthalidone. Approved Cholestyramine Cholestyramine can cause a decrease in the absorption of Mometasone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Choline magnesium trisalicylate The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Mometasone. Approved Cinoxacin The risk or severity of adverse effects can be increased when Mometasone is combined with Cinoxacin. Approved, Investigational, Withdrawn Clarithromycin The serum concentration of Mometasone can be increased when it is combined with Clarithromycin. Approved Clonixin The risk or severity of adverse effects can be increased when Clonixin is combined with Mometasone. Approved Clostridium tetani toxoid antigen (formaldehyde inactivated) The risk or severity of adverse effects can be increased when Mometasone is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated). Approved Cobicistat The serum concentration of Mometasone can be increased when it is combined with Cobicistat. Approved Colesevelam Colesevelam can cause a decrease in the absorption of Mometasone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Colestipol Colestipol can cause a decrease in the absorption of Mometasone resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Conjugated estrogens The serum concentration of Mometasone can be increased when it is combined with Conjugated estrogens. Approved Corticorelin ovine triflutate The therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Mometasone. Approved Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) The risk or severity of adverse effects can be increased when Mometasone is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated). Approved Coumaphos The risk or severity of adverse effects can be increased when Mometasone is combined with Coumaphos. Vet Approved Curcumin The risk or severity of adverse effects can be increased when Curcumin is combined with Mometasone. Approved, Investigational Cyclopenthiazide Mometasone may increase the hypokalemic activities of Cyclopenthiazide. Experimental Daidzein The serum concentration of Mometasone can be increased when it is combined with Daidzein. Experimental Danazol Mometasone may increase the fluid retaining activities of Danazol. Approved Darunavir The serum concentration of Mometasone can be increased when it is combined with Darunavir. Approved Decamethonium The risk or severity of adverse effects can be increased when Mometasone is combined with Decamethonium. Approved Deferasirox The risk or severity of adverse effects can be increased when Mometasone is combined with Deferasirox. Approved, Investigational Demecarium The risk or severity of adverse effects can be increased when Mometasone is combined with Demecarium. Approved Dersalazine The risk or severity of adverse effects can be increased when Dersalazine is combined with Mometasone. Investigational Dichlorvos The risk or severity of adverse effects can be increased when Mometasone is combined with Dichlorvos. Vet Approved Diclofenac The risk or severity of adverse effects can be increased when Diclofenac is combined with Mometasone. Approved, Vet Approved Dienestrol The serum concentration of Mometasone can be increased when it is combined with Dienestrol. Approved, Investigational Diethylstilbestrol The serum concentration of Mometasone can be increased when it is combined with Diethylstilbestrol. Approved, Investigational Difenpiramide The risk or severity of adverse effects can be increased when Difenpiramide is combined with Mometasone. Experimental Diflunisal The risk or severity of adverse effects can be increased when Diflunisal is combined with Mometasone. Approved, Investigational Distigmine The risk or severity of adverse effects can be increased when Mometasone is combined with Distigmine. Experimental Donepezil The risk or severity of adverse effects can be increased when Mometasone is combined with Donepezil. Approved Droxicam The risk or severity of adverse effects can be increased when Droxicam is combined with Mometasone. Withdrawn Duvelisib The risk or severity of adverse effects can be increased when Duvelisib is combined with Mometasone. Investigational E-6201 The risk or severity of adverse effects can be increased when E-6201 is combined with Mometasone. Investigational Echothiophate The risk or severity of adverse effects can be increased when Mometasone is combined with Echothiophate. Approved Edrophonium The risk or severity of adverse effects can be increased when Mometasone is combined with Edrophonium. Approved Enoxacin The risk or severity of adverse effects can be increased when Mometasone is combined with Enoxacin. Approved, Investigational Enzalutamide The serum concentration of Mometasone can be decreased when it is combined with Enzalutamide. Approved Epimestrol The serum concentration of Mometasone can be increased when it is combined with Epimestrol. Experimental Epirizole The risk or severity of adverse effects can be increased when Epirizole is combined with Mometasone. Approved Epitizide Mometasone may increase the hypokalemic activities of Epitizide. Experimental Equol The serum concentration of Mometasone can be increased when it is combined with Equol. Investigational Estradiol The serum concentration of Mometasone can be increased when it is combined with Estradiol. Approved, Investigational, Vet Approved Estradiol acetate The serum concentration of Mometasone can be increased when it is combined with Estradiol acetate. Approved, Investigational, Vet Approved Estradiol cypionate The serum concentration of Mometasone can be increased when it is combined with Estradiol cypionate. Approved, Investigational, Vet Approved Estradiol valerate The serum concentration of Mometasone can be increased when it is combined with Estradiol valerate. Approved, Investigational, Vet Approved Estriol The serum concentration of Mometasone can be increased when it is combined with Estriol. Approved, Investigational, Vet Approved Estrogens, esterified The serum concentration of Mometasone can be increased when it is combined with Estrogens, esterified. Approved Estrone The serum concentration of Mometasone can be increased when it is combined with Estrone. Approved Etacrynic acid Mometasone may increase the hypokalemic activities of Etacrynic acid. Approved, Investigational Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Mometasone. Approved, Investigational Ethenzamide The risk or severity of adverse effects can be increased when Ethenzamide is combined with Mometasone. Experimental Ethinyl Estradiol The serum concentration of Mometasone can be increased when it is combined with Ethinyl Estradiol. Approved Etodolac The risk or severity of adverse effects can be increased when Etodolac is combined with Mometasone. Approved, Investigational, Vet Approved Etofenamate The risk or severity of adverse effects can be increased when Etofenamate is combined with Mometasone. Approved, Investigational Etoricoxib The risk or severity of adverse effects can be increased when Etoricoxib is combined with Mometasone. Approved, Investigational Evening primrose oil The risk or severity of adverse effects can be increased when Evening primrose oil is combined with Mometasone. Investigational, Nutraceutical Exisulind The risk or severity of adverse effects can be increased when Exisulind is combined with Mometasone. Investigational Felbinac The risk or severity of adverse effects can be increased when Felbinac is combined with Mometasone. Experimental Fenbufen The risk or severity of adverse effects can be increased when Fenbufen is combined with Mometasone. Approved Fenoprofen The risk or severity of adverse effects can be increased when Fenoprofen is combined with Mometasone. Approved Fenthion The risk or severity of adverse effects can be increased when Mometasone is combined with Fenthion. Vet Approved Fentiazac The risk or severity of adverse effects can be increased when Fentiazac is combined with Mometasone. Experimental Feprazone The risk or severity of adverse effects can be increased when Feprazone is combined with Mometasone. Experimental Ferulic acid The risk or severity of adverse effects can be increased when Ferulic acid is combined with Mometasone. Experimental Fleroxacin The risk or severity of adverse effects can be increased when Mometasone is combined with Fleroxacin. Approved Floctafenine The risk or severity of adverse effects can be increased when Floctafenine is combined with Mometasone. Approved, Withdrawn Flumequine The risk or severity of adverse effects can be increased when Mometasone is combined with Flumequine. Withdrawn Flunixin The risk or severity of adverse effects can be increased when Flunixin is combined with Mometasone. Vet Approved Flunoxaprofen The risk or severity of adverse effects can be increased when Flunoxaprofen is combined with Mometasone. Experimental Fluoxymesterone Mometasone may increase the fluid retaining activities of Fluoxymesterone. Approved, Illicit Flurbiprofen The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Mometasone. Approved, Investigational Fosaprepitant The serum concentration of Mometasone can be increased when it is combined with Fosaprepitant. Approved Fosphenytoin The serum concentration of Mometasone can be decreased when it is combined with Fosphenytoin. Approved, Investigational Furosemide Mometasone may increase the hypokalemic activities of Furosemide. Approved, Vet Approved G17DT The risk or severity of adverse effects can be increased when Mometasone is combined with G17DT. Investigational Galantamine The risk or severity of adverse effects can be increased when Mometasone is combined with Galantamine. Approved Gallamine Triethiodide The risk or severity of adverse effects can be increased when Mometasone is combined with Gallamine Triethiodide. Approved Garenoxacin The risk or severity of adverse effects can be increased when Mometasone is combined with Garenoxacin. Investigational Gatifloxacin The risk or severity of adverse effects can be increased when Mometasone is combined with Gatifloxacin. Approved, Investigational Gemifloxacin The risk or severity of adverse effects can be increased when Mometasone is combined with Gemifloxacin. Approved, Investigational Genistein The serum concentration of Mometasone can be increased when it is combined with Genistein. Investigational GI-5005 The risk or severity of adverse effects can be increased when Mometasone is combined with GI-5005. Investigational GLPG-0492 Mometasone may increase the fluid retaining activities of GLPG-0492. Investigational Glycerol Phenylbutyrate The therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Mometasone. Approved Grepafloxacin The risk or severity of adverse effects can be increased when Mometasone is combined with Grepafloxacin. Approved, Investigational, Withdrawn Guacetisal The risk or severity of adverse effects can be increased when Guacetisal is combined with Mometasone. Experimental Hemoglobin crosfumaril The risk or severity of adverse effects can be increased when Hemoglobin crosfumaril is combined with Mometasone. Experimental Hepatitis A Vaccine The risk or severity of adverse effects can be increased when Mometasone is combined with Hepatitis A Vaccine. Approved Hepatitis B Vaccine (Recombinant) The risk or severity of adverse effects can be increased when Mometasone is combined with Hepatitis B Vaccine (Recombinant). Approved, Withdrawn Hexestrol The serum concentration of Mometasone can be increased when it is combined with Hexestrol. Withdrawn Higenamine The risk or severity of adverse effects can be increased when Higenamine is combined with Mometasone. Investigational Human rabies virus immune globulin The risk or severity of adverse effects can be increased when Mometasone is combined with Human rabies virus immune globulin. Approved Huperzine A The risk or severity of adverse effects can be increased when Mometasone is combined with Huperzine A. Approved, Investigational Hyaluronidase The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Mometasone. Approved, Investigational Hydrochlorothiazide Mometasone may increase the hypokalemic activities of Hydrochlorothiazide. Approved, Vet Approved Hydroflumethiazide Mometasone may increase the hypokalemic activities of Hydroflumethiazide. Approved, Investigational Hydrotalcite The bioavailability of Mometasone can be decreased when combined with Hydrotalcite. Approved, Experimental, Investigational Ibuprofen The risk or severity of adverse effects can be increased when Ibuprofen is combined with Mometasone. Approved Ibuproxam The risk or severity of adverse effects can be increased when Ibuproxam is combined with Mometasone. Withdrawn Icatibant The risk or severity of adverse effects can be increased when Icatibant is combined with Mometasone. Approved, Investigational Idelalisib The serum concentration of Mometasone can be increased when it is combined with Idelalisib. Approved Imidazole salicylate The risk or severity of adverse effects can be increased when Imidazole salicylate is combined with Mometasone. Experimental Indacaterol Indacaterol may increase the hypokalemic activities of Mometasone. Approved Indapamide Mometasone may increase the hypokalemic activities of Indapamide. Approved Indinavir The serum concentration of Mometasone can be increased when it is combined with Indinavir. Approved Indobufen The risk or severity of adverse effects can be increased when Indobufen is combined with Mometasone. Investigational Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Mometasone. Approved, Investigational Indoprofen The risk or severity of adverse effects can be increased when Indoprofen is combined with Mometasone. Withdrawn INGN 201 The risk or severity of adverse effects can be increased when Mometasone is combined with INGN 201. Investigational INGN 225 The risk or severity of adverse effects can be increased when Mometasone is combined with INGN 225. Investigational Ipidacrine The risk or severity of adverse effects can be increased when Mometasone is combined with Ipidacrine. Experimental Isoflurophate The risk or severity of adverse effects can be increased when Mometasone is combined with Isoflurophate. Approved, Investigational, Withdrawn Isoniazid The serum concentration of Isoniazid can be decreased when it is combined with Mometasone. Approved, Investigational Isoxicam The risk or severity of adverse effects can be increased when Isoxicam is combined with Mometasone. Withdrawn Itraconazole The serum concentration of Mometasone can be increased when it is combined with Itraconazole. Approved, Investigational Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) The risk or severity of adverse effects can be increased when Mometasone is combined with Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated). Approved Kebuzone The risk or severity of adverse effects can be increased when Kebuzone is combined with Mometasone. Experimental Ketoconazole The serum concentration of Mometasone can be increased when it is combined with Ketoconazole. Approved, Investigational Ketoprofen The risk or severity of adverse effects can be increased when Ketoprofen is combined with Mometasone. Approved, Vet Approved Ketorolac The risk or severity of adverse effects can be increased when Ketorolac is combined with Mometasone. Approved Lacidipine The serum concentration of Lacidipine can be decreased when it is combined with Mometasone. Approved, Investigational Leflunomide The risk or severity of adverse effects can be increased when Leflunomide is combined with Mometasone. Approved, Investigational Levofloxacin The risk or severity of adverse effects can be increased when Mometasone is combined with Levofloxacin. Approved, Investigational Lisofylline The risk or severity of adverse effects can be increased when Lisofylline is combined with Mometasone. Investigational Lonazolac The risk or severity of adverse effects can be increased when Lonazolac is combined with Mometasone. Experimental Lopinavir The serum concentration of Mometasone can be increased when it is combined with Lopinavir. Approved Lornoxicam The risk or severity of adverse effects can be increased when Lornoxicam is combined with Mometasone. Approved, Investigational Loxapine The therapeutic efficacy of Mometasone can be decreased when used in combination with Loxapine. Approved Loxoprofen The risk or severity of adverse effects can be increased when Loxoprofen is combined with Mometasone. Approved, Investigational Lumacaftor The serum concentration of Mometasone can be decreased when it is combined with Lumacaftor. Approved Lumiracoxib The risk or severity of adverse effects can be increased when Lumiracoxib is combined with Mometasone. Approved, Investigational Magaldrate The bioavailability of Mometasone can be decreased when combined with Magaldrate. Approved, Withdrawn Magnesium hydroxide The bioavailability of Mometasone can be decreased when combined with Magnesium hydroxide. Approved, Investigational Magnesium oxide The bioavailability of Mometasone can be decreased when combined with Magnesium oxide. Approved Magnesium peroxide The bioavailability of Mometasone can be decreased when combined with Magnesium peroxide. Experimental Magnesium salicylate The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Mometasone. Approved Magnesium silicate The bioavailability of Mometasone can be decreased when combined with Magnesium silicate. Approved Magnesium Trisilicate The bioavailability of Mometasone can be decreased when combined with Magnesium Trisilicate. Approved Malathion The risk or severity of adverse effects can be increased when Mometasone is combined with Malathion. Approved, Investigational Masoprocol The risk or severity of adverse effects can be increased when Masoprocol is combined with Mometasone. Approved, Investigational Meclofenamic acid The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Mometasone. Approved, Vet Approved Mefenamic acid The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Mometasone. Approved Mefloquine The risk or severity of adverse effects can be increased when Mometasone is combined with Mefloquine. Approved, Investigational Meloxicam The risk or severity of adverse effects can be increased when Meloxicam is combined with Mometasone. Approved, Vet Approved Memantine The risk or severity of adverse effects can be increased when Mometasone is combined with Memantine. Approved, Investigational Mesalazine The risk or severity of adverse effects can be increased when Mesalazine is combined with Mometasone. Approved Mesterolone Mometasone may increase the fluid retaining activities of Mesterolone. Experimental Mestranol The serum concentration of Mometasone can be increased when it is combined with Mestranol. Approved Metamizole The risk or severity of adverse effects can be increased when Metamizole is combined with Mometasone. Approved, Investigational, Withdrawn Methallenestril The serum concentration of Mometasone can be increased when it is combined with Methallenestril. Experimental Methanesulfonyl Fluoride The risk or severity of adverse effects can be increased when Mometasone is combined with Methanesulfonyl Fluoride. Investigational Methyclothiazide Mometasone may increase the hypokalemic activities of Methyclothiazide. Approved Methyl salicylate The risk or severity of adverse effects can be increased when Methyl salicylate is combined with Mometasone. Approved, Vet Approved Methyltestosterone Mometasone may increase the fluid retaining activities of Methyltestosterone. Approved Metoclopramide The risk or severity of adverse effects can be increased when Mometasone is combined with Metoclopramide. Approved, Investigational Metolazone Mometasone may increase the hypokalemic activities of Metolazone. Approved Mifepristone The therapeutic efficacy of Mometasone can be decreased when used in combination with Mifepristone. Approved, Investigational Minaprine The risk or severity of adverse effects can be increased when Mometasone is combined with Minaprine. Approved Mitotane The serum concentration of Mometasone can be decreased when it is combined with Mitotane. Approved Mivacurium Mivacurium may increase the adverse neuromuscular activities of Mometasone. Approved Mizoribine The risk or severity of adverse effects can be increased when Mizoribine is combined with Mometasone. Investigational Mofebutazone The risk or severity of adverse effects can be increased when Mofebutazone is combined with Mometasone. Experimental Moxestrol The serum concentration of Mometasone can be increased when it is combined with Moxestrol. Experimental Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Mometasone. Approved, Investigational Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Mometasone. Approved Nabumetone The risk or severity of adverse effects can be increased when Nabumetone is combined with Mometasone. Approved Nafamostat The risk or severity of adverse effects can be increased when Nafamostat is combined with Mometasone. Approved, Investigational Naftifine The risk or severity of adverse effects can be increased when Naftifine is combined with Mometasone. Approved Nalidixic Acid The risk or severity of adverse effects can be increased when Mometasone is combined with Nalidixic Acid. Approved, Investigational Nandrolone Mometasone may increase the fluid retaining activities of Nandrolone. Experimental, Investigational Nandrolone decanoate Mometasone may increase the fluid retaining activities of Nandrolone decanoate. Approved, Illicit Naproxen The risk or severity of adverse effects can be increased when Naproxen is combined with Mometasone. Approved, Vet Approved Nefazodone The serum concentration of Mometasone can be increased when it is combined with Nefazodone. Approved, Withdrawn Nelfinavir The serum concentration of Mometasone can be increased when it is combined with Nelfinavir. Approved Nemonoxacin The risk or severity of adverse effects can be increased when Mometasone is combined with Nemonoxacin. Investigational Neostigmine The risk or severity of adverse effects can be increased when Mometasone is combined with Neostigmine. Approved, Vet Approved Nepafenac The risk or severity of adverse effects can be increased when Nepafenac is combined with Mometasone. Approved, Investigational Nevirapine The serum concentration of Mometasone can be decreased when it is combined with Nevirapine. Approved Nicorandil The risk or severity of adverse effects can be increased when Mometasone is combined with Nicorandil. Approved, Investigational Nifenazone The risk or severity of adverse effects can be increased when Nifenazone is combined with Mometasone. Experimental Niflumic Acid The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Mometasone. Approved Nimesulide The risk or severity of adverse effects can be increased when Nimesulide is combined with Mometasone. Approved, Investigational, Withdrawn Nitroaspirin The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Mometasone. Investigational Norfloxacin The risk or severity of adverse effects can be increased when Mometasone is combined with Norfloxacin. Approved Olopatadine The risk or severity of adverse effects can be increased when Olopatadine is combined with Mometasone. Approved Olsalazine The risk or severity of adverse effects can be increased when Olsalazine is combined with Mometasone. Approved Orgotein The risk or severity of adverse effects can be increased when Orgotein is combined with Mometasone. Vet Approved Oxandrolone Mometasone may increase the fluid retaining activities of Oxandrolone. Approved, Investigational Oxaprozin The risk or severity of adverse effects can be increased when Oxaprozin is combined with Mometasone. Approved Oxolinic acid The risk or severity of adverse effects can be increased when Mometasone is combined with Oxolinic acid. Experimental Oxymetholone Mometasone may increase the fluid retaining activities of Oxymetholone. Approved, Illicit Oxyphenbutazone The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Mometasone. Approved, Withdrawn Paraoxon The risk or severity of adverse effects can be increased when Mometasone is combined with Paraoxon. Experimental Parecoxib The risk or severity of adverse effects can be increased when Parecoxib is combined with Mometasone. Approved Parthenolide The risk or severity of adverse effects can be increased when Parthenolide is combined with Mometasone. Approved, Investigational Pazufloxacin The risk or severity of adverse effects can be increased when Mometasone is combined with Pazufloxacin. Investigational Pefloxacin The risk or severity of adverse effects can be increased when Mometasone is combined with Pefloxacin. Approved Pentobarbital The serum concentration of Mometasone can be decreased when it is combined with Pentobarbital. Approved, Investigational, Vet Approved Phenobarbital The serum concentration of Mometasone can be decreased when it is combined with Phenobarbital. Approved, Investigational Phenyl aminosalicylate The risk or severity of adverse effects can be increased when Phenyl aminosalicylate is combined with Mometasone. Approved Phenylacetic acid The therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Mometasone. Approved Phenylbutazone The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Mometasone. Approved, Vet Approved Phenylbutyric acid The therapeutic efficacy of Phenylbutyric acid can be decreased when used in combination with Mometasone. Approved, Investigational Phenytoin The serum concentration of Mometasone can be decreased when it is combined with Phenytoin. Approved, Vet Approved Physostigmine The risk or severity of adverse effects can be increased when Mometasone is combined with Physostigmine. Approved, Investigational Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mometasone. Approved, Investigational Pipemidic acid The risk or severity of adverse effects can be increased when Mometasone is combined with Pipemidic acid. Experimental Piretanide Mometasone may increase the hypokalemic activities of Piretanide. Approved Pirfenidone The risk or severity of adverse effects can be increased when Pirfenidone is combined with Mometasone. Approved, Investigational Piromidic acid The risk or severity of adverse effects can be increased when Mometasone is combined with Piromidic acid. Experimental Piroxicam The risk or severity of adverse effects can be increased when Piroxicam is combined with Mometasone. Approved, Investigational Pirprofen The risk or severity of adverse effects can be increased when Pirprofen is combined with Mometasone. Experimental Polyestradiol phosphate The serum concentration of Mometasone can be increased when it is combined with Polyestradiol phosphate. Approved Polythiazide Mometasone may increase the hypokalemic activities of Polythiazide. Approved Posaconazole The serum concentration of Mometasone can be increased when it is combined with Posaconazole. Approved, Investigational, Vet Approved Pranoprofen The risk or severity of adverse effects can be increased when Pranoprofen is combined with Mometasone. Experimental, Investigational Primidone The serum concentration of Mometasone can be decreased when it is combined with Primidone. Approved, Vet Approved Proglumetacin The risk or severity of adverse effects can be increased when Proglumetacin is combined with Mometasone. Experimental Promestriene The serum concentration of Mometasone can be increased when it is combined with Promestriene. Investigational Propacetamol The risk or severity of adverse effects can be increased when Propacetamol is combined with Mometasone. Approved, Investigational Propyphenazone The risk or severity of adverse effects can be increased when Propyphenazone is combined with Mometasone. Experimental Proquazone The risk or severity of adverse effects can be increased when Proquazone is combined with Mometasone. Experimental Prulifloxacin The risk or severity of adverse effects can be increased when Mometasone is combined with Prulifloxacin. Investigational PTC299 The risk or severity of adverse effects can be increased when PTC299 is combined with Mometasone. Investigational Pyridostigmine The risk or severity of adverse effects can be increased when Mometasone is combined with Pyridostigmine. Approved, Investigational Quinestrol The serum concentration of Mometasone can be increased when it is combined with Quinestrol. Approved Quinethazone Mometasone may increase the hypokalemic activities of Quinethazone. Approved Rabies virus inactivated antigen, A The risk or severity of adverse effects can be increased when Mometasone is combined with Rabies virus inactivated antigen, A. Approved, Investigational Rapacuronium Rapacuronium may increase the adverse neuromuscular activities of Mometasone. Withdrawn Resveratrol The risk or severity of adverse effects can be increased when Resveratrol is combined with Mometasone. Approved, Experimental, Investigational Rifabutin The serum concentration of Mometasone can be decreased when it is combined with Rifabutin. Approved, Investigational Rifampicin The serum concentration of Mometasone can be decreased when it is combined with Rifampicin. Approved Rifapentine The serum concentration of Mometasone can be decreased when it is combined with Rifapentine. Approved, Investigational Rindopepimut The risk or severity of adverse effects can be increased when Mometasone is combined with Rindopepimut. Investigational Rivastigmine The risk or severity of adverse effects can be increased when Mometasone is combined with Rivastigmine. Approved, Investigational Rofecoxib The risk or severity of adverse effects can be increased when Rofecoxib is combined with Mometasone. Approved, Investigational, Withdrawn Rosoxacin The risk or severity of adverse effects can be increased when Mometasone is combined with Rosoxacin. Approved, Investigational Rotavirus Vaccine The risk or severity of adverse effects can be increased when Mometasone is combined with Rotavirus Vaccine. Approved Rubella virus vaccine The risk or severity of adverse effects can be increased when Mometasone is combined with Rubella virus vaccine. Approved, Investigational Rufloxacin The risk or severity of adverse effects can be increased when Mometasone is combined with Rufloxacin. Experimental Salicylamide The risk or severity of adverse effects can be increased when Salicylamide is combined with Mometasone. Approved Salicylic acid The risk or severity of adverse effects can be increased when Salicylic acid is combined with Mometasone. Approved, Investigational, Vet Approved Salmonella typhi ty2 vi polysaccharide antigen The risk or severity of adverse effects can be increased when Mometasone is combined with Salmonella typhi ty2 vi polysaccharide antigen. Approved Salmonella typhi ty21a live antigen The risk or severity of adverse effects can be increased when Mometasone is combined with Salmonella typhi ty21a live antigen. Approved Salsalate The risk or severity of adverse effects can be increased when Salsalate is combined with Mometasone. Approved Saquinavir The serum concentration of Mometasone can be increased when it is combined with Saquinavir. Approved, Investigational Secoisolariciresinol The serum concentration of Mometasone can be increased when it is combined with Secoisolariciresinol. Investigational Semapimod The risk or severity of adverse effects can be increased when Semapimod is combined with Mometasone. Investigational Seratrodast The risk or severity of adverse effects can be increased when Seratrodast is combined with Mometasone. Approved Serrapeptase The risk or severity of adverse effects can be increased when Serrapeptase is combined with Mometasone. Investigational Sitafloxacin The risk or severity of adverse effects can be increased when Mometasone is combined with Sitafloxacin. Experimental, Investigational Sodium bicarbonate The bioavailability of Mometasone can be decreased when combined with Sodium bicarbonate. Approved Sparfloxacin The risk or severity of adverse effects can be increased when Mometasone is combined with Sparfloxacin. Approved, Investigational SRP 299 The risk or severity of adverse effects can be increased when Mometasone is combined with SRP 299. Investigational SRT501 The risk or severity of adverse effects can be increased when SRT501 is combined with Mometasone. Investigational St. John's Wort The serum concentration of Mometasone can be decreased when it is combined with St. John's Wort. Approved, Investigational, Nutraceutical Stanolone Mometasone may increase the fluid retaining activities of Stanolone. Illicit, Investigational Stanozolol Mometasone may increase the fluid retaining activities of Stanozolol. Approved, Vet Approved Stiripentol The serum concentration of Mometasone can be increased when it is combined with Stiripentol. Approved Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Mometasone. Approved Sulindac The risk or severity of adverse effects can be increased when Sulindac is combined with Mometasone. Approved, Investigational Suprofen The risk or severity of adverse effects can be increased when Suprofen is combined with Mometasone. Approved, Withdrawn Suxibuzone The risk or severity of adverse effects can be increased when Suxibuzone is combined with Mometasone. Experimental Synthetic Conjugated Estrogens, A The serum concentration of Mometasone can be increased when it is combined with Synthetic Conjugated Estrogens, A. Approved Synthetic Conjugated Estrogens, B The serum concentration of Mometasone can be increased when it is combined with Synthetic Conjugated Estrogens, B. Approved Tacrine The risk or severity of adverse effects can be increased when Mometasone is combined with Tacrine. Investigational, Withdrawn Tarenflurbil The risk or severity of adverse effects can be increased when Tarenflurbil is combined with Mometasone. Investigational Tecemotide The risk or severity of adverse effects can be increased when Mometasone is combined with Tecemotide. Investigational Telaprevir The serum concentration of Telaprevir can be decreased when it is combined with Mometasone. Approved, Withdrawn Telithromycin The serum concentration of Mometasone can be increased when it is combined with Telithromycin. Approved Temafloxacin The risk or severity of adverse effects can be increased when Mometasone is combined with Temafloxacin. Withdrawn Tenidap The risk or severity of adverse effects can be increased when Tenidap is combined with Mometasone. Experimental Tenoxicam The risk or severity of adverse effects can be increased when Tenoxicam is combined with Mometasone. Approved Tepoxalin The risk or severity of adverse effects can be increased when Tepoxalin is combined with Mometasone. Vet Approved Teriflunomide The risk or severity of adverse effects can be increased when Teriflunomide is combined with Mometasone. Approved Testosterone Mometasone may increase the fluid retaining activities of Testosterone. Approved, Investigational Testosterone cypionate The risk or severity of edema formation can be increased when Testosterone cypionate is combined with Mometasone. Approved Testosterone enanthate The risk or severity of edema formation can be increased when Testosterone enanthate is combined with Mometasone. Approved Testosterone propionate Mometasone may increase the fluid retaining activities of Testosterone propionate. Approved, Investigational, Vet Approved, Withdrawn Testosterone undecanoate The risk or severity of fluid retention can be increased when Testosterone undecanoate is combined with Mometasone. Approved, Investigational TG4010 The risk or severity of adverse effects can be increased when Mometasone is combined with TG4010. Investigational Tiaprofenic acid The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Mometasone. Approved Tibolone The serum concentration of Mometasone can be increased when it is combined with Tibolone. Approved, Investigational Tinoridine The risk or severity of adverse effects can be increased when Tinoridine is combined with Mometasone. Investigational Tolfenamic Acid The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Mometasone. Approved, Investigational Tolmetin The risk or severity of adverse effects can be increased when Tolmetin is combined with Mometasone. Approved Torasemide Mometasone may increase the hypokalemic activities of Torasemide. Approved Tranilast The risk or severity of adverse effects can be increased when Tranilast is combined with Mometasone. Approved, Investigational Tribenoside The risk or severity of adverse effects can be increased when Tribenoside is combined with Mometasone. Experimental Trichlorfon The risk or severity of adverse effects can be increased when Mometasone is combined with Trichlorfon. Vet Approved Trichlormethiazide Mometasone may increase the hypokalemic activities of Trichlormethiazide. Approved, Vet Approved Triptolide The risk or severity of adverse effects can be increased when Triptolide is combined with Mometasone. Investigational Trolamine salicylate The risk or severity of adverse effects can be increased when Trolamine salicylate is combined with Mometasone. Approved Tromethamine The bioavailability of Mometasone can be decreased when combined with Tromethamine. Approved Trovafloxacin The risk or severity of adverse effects can be increased when Mometasone is combined with Trovafloxacin. Approved, Investigational, Withdrawn Tubocurarine The risk or severity of adverse effects can be increased when Mometasone is combined with Tubocurarine. Approved Tyrothricin The risk or severity of adverse effects can be increased when Mometasone is combined with Tyrothricin. Approved Valdecoxib The risk or severity of adverse effects can be increased when Valdecoxib is combined with Mometasone. Approved, Investigational, Withdrawn Varicella Zoster Vaccine (Live/Attenuated) The risk or severity of adverse effects can be increased when Mometasone is combined with Varicella Zoster Vaccine (Live/Attenuated). Approved Voriconazole The serum concentration of Mometasone can be increased when it is combined with Voriconazole. Approved, Investigational Warfarin Mometasone may increase the anticoagulant activities of Warfarin. Approved Yellow Fever Vaccine The risk or severity of adverse effects can be increased when Mometasone is combined with Yellow Fever Vaccine. Approved, Investigational Zaltoprofen The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Mometasone. Approved, Investigational Zeranol The serum concentration of Mometasone can be increased when it is combined with Zeranol. Vet Approved Zileuton The risk or severity of adverse effects can be increased when Zileuton is combined with Mometasone. Approved, Investigational, Withdrawn Zomepirac The risk or severity of adverse effects can be increased when Zomepirac is combined with Mometasone. Withdrawn - Food Interactions
- Not Available
References
- Synthesis Reference
Pui-Ho Yuen, Charles Eckhart, Teresa Etlinger, Nancy Levine, "Mometasone furoate monohydrate, process for making same and pharmaceutical compositions." U.S. Patent US6127353, issued April, 1988.
US6127353- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0014902
- KEGG Drug
- D08227
- KEGG Compound
- C07816
- PubChem Compound
- 441335
- PubChem Substance
- 46505288
- ChemSpider
- 390090
- ChEBI
- 6970
- ChEMBL
- CHEMBL1201404
- Therapeutic Targets Database
- DAP001042
- PharmGKB
- PA450541
- HET
- MOF
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- PDRhealth
- PDRhealth Drug Page
- Wikipedia
- Mometasone
- ATC Codes
- R03BA07 — Mometasone
- R03BA — Glucocorticoids
- R03B — OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS
- R03 — DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
- R — RESPIRATORY SYSTEM
- R01AD — Corticosteroids
- R01A — DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
- R01 — NASAL PREPARATIONS
- R — RESPIRATORY SYSTEM
- R03AK — Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
- R03A — ADRENERGICS, INHALANTS
- R03 — DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
- R — RESPIRATORY SYSTEM
- D07XC — Corticosteroids, potent, other combinations
- D07X — CORTICOSTEROIDS, OTHER COMBINATIONS
- D07 — CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
- D — DERMATOLOGICALS
- AHFS Codes
- 68:04.00 — Adrenals
- 84:06.00 — Anti-inflammatory Agents
- 52:08.08 — Corticosteroids
- FDA label
- Download (152 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Schering corp sub schering plough corp
- Altana inc
- G and w laboratories inc
- Glenmark generics inc usa
- Taro pharmaceuticals usa inc
- Tolmar inc
- Nycomed us inc
- Perrigo co
- Perrigo new york inc
- Schering corp
- Schering plough healthcare products inc
- Schering-Plough
- Packagers
- A-S Medication Solutions LLC
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- Dixie Chem Tec Inc.
- E. Fougera and Co.
- G & W Labs
- Glenmark Generics Ltd.
- Harris Pharmaceutical Inc.
- JSJ Pharmaceuticals Inc.
- Lake Erie Medical and Surgical Supply
- Nycomed Inc.
- Perrigo Co.
- Pharmedix
- Physicians Total Care Inc.
- Sandoz
- Schering Corp.
- Schering-Plough Inc.
- Taro Pharmaceuticals USA
- Tolmar Inc.
- Dosage forms
Form Route Strength Inhalant Respiratory (inhalation) 110 ug/1 Inhalant Respiratory (inhalation) 220 ug/1 Aerosol Respiratory (inhalation) 100 ug/1 Aerosol Respiratory (inhalation) 200 ug/1 Powder Respiratory (inhalation) 100 mcg Powder Respiratory (inhalation) 200 mcg Powder Respiratory (inhalation) 400 mcg Aerosol Respiratory (inhalation) Cream Topical 0.1 % Lotion Topical 0.1 % Ointment Topical 0.1 % Cream Topical 1 mg/g Lotion Topical 1 mg/g Lotion Topical 1 mg/mL Ointment Topical 1 mg/g Solution Topical 1 mg/mL Spray, metered Nasal 50 ug/1 Spray, metered Nasal 50 mcg Cream Topical .1 % Lotion Topical .1 % Implant Intrasinal 1350 ug/1 Aerosol, metered Respiratory (inhalation) - Prices
Unit description Cost Unit Asmanex 120 Metered Doses 220 mcg/inh Aerosol 0.24 gm Inhaler 230.27USD inhaler Asmanex twisthaler 220 mcg #30 131.47USD inhaler Asmanex twisthaler 110 mcg #30 121.76USD inhaler Nasonex 50 mcg/act Suspension 50 mcg Nasal Spray 116.82USD inhaler Elocon 0.1% Lotion 60ml Bottle 86.71USD bottle Elocon 0.1% Cream 45 gm Tube 79.13USD tube Elocon 0.1% Ointment 45 gm Tube 76.45USD tube Mometasone Furoate 0.1% Solution 60ml Bottle 64.99USD bottle Mometasone Furoate 0.1% Cream 45 gm Tube 50.96USD tube Elocon 0.1% Lotion 30ml Bottle 49.85USD bottle Elocon 0.1% Ointment 15 gm Tube 49.85USD tube Elocon 0.1% Cream 15 gm Tube 47.68USD tube Mometasone Furoate 0.1% Ointment 45 gm Tube 35.99USD tube Mometasone Furoate 0.1% Solution 30ml Bottle 32.99USD bottle Mometasone Furoate 0.1% Cream 15 gm Tube 29.99USD tube Mometasone Furoate 0.1% Ointment 15 gm Tube 19.19USD tube Nasonex 50 mcg nasal spray 6.37USD g Elocon 0.1% cream 2.69USD g Mometasone furoate 0.1% cream 1.42USD g Elocom 0.1 % Cream 0.7USD g Elocom 0.1 % Ointment 0.63USD g Elocom 0.1 % Lotion 0.47USD g Pms-Mometasone 0.1 % Ointment 0.35USD g Ratio-Mometasone 0.1 % Ointment 0.35USD g Taro-Mometasone 0.1 % Ointment 0.35USD g Taro-Mometasone 0.1 % Lotion 0.33USD g DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) US5394868 No 1995-06-25 2012-06-25 US CA2282360 No 2004-11-09 2018-03-16 Canada CA2091360 No 1997-04-08 2011-09-06 Canada US6127353 Yes 1998-04-03 2018-04-03 US US6240918 Yes 1997-08-20 2017-08-20 US US8173172 Yes 1998-09-17 2018-09-17 US US6503537 Yes 1998-09-17 2018-09-17 US US5829434 Yes 1996-05-03 2016-05-03 US US6068832 No 1997-08-27 2017-08-27 US US7067502 No 2000-05-21 2020-05-21 US US7566705 No 2000-05-21 2020-05-21 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 218-220 °C Not Available water solubility Practically insoluble. Not Available logP 2.1 Not Available - Predicted Properties
Property Value Source Water Solubility 0.00523 mg/mL ALOGPS logP 2.81 ALOGPS logP 3.5 ChemAxon logS -4.9 ALOGPS pKa (Strongest Acidic) 12.48 ChemAxon pKa (Strongest Basic) -3.3 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 74.6 Å2 ChemAxon Rotatable Bond Count 2 ChemAxon Refractivity 110.29 m3·mol-1 ChemAxon Polarizability 43.82 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 0.995 Blood Brain Barrier + 0.9721 Caco-2 permeable + 0.7845 P-glycoprotein substrate Substrate 0.7849 P-glycoprotein inhibitor I Non-inhibitor 0.7635 P-glycoprotein inhibitor II Non-inhibitor 0.656 Renal organic cation transporter Non-inhibitor 0.7753 CYP450 2C9 substrate Non-substrate 0.852 CYP450 2D6 substrate Non-substrate 0.9135 CYP450 3A4 substrate Substrate 0.8028 CYP450 1A2 substrate Non-inhibitor 0.9383 CYP450 2C9 inhibitor Non-inhibitor 0.8572 CYP450 2D6 inhibitor Non-inhibitor 0.8429 CYP450 2C19 inhibitor Non-inhibitor 0.8966 CYP450 3A4 inhibitor Non-inhibitor 0.6761 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8898 Ames test Non AMES toxic 0.8962 Carcinogenicity Non-carcinogens 0.9393 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 1.9124 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9254 hERG inhibition (predictor II) Non-inhibitor 0.6092
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as gluco/mineralocorticoids, progestogins and derivatives. These are steroids with a structure based on a hydroxylated prostane moiety.
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Steroids and steroid derivatives
- Sub Class
- Pregnane steroids
- Direct Parent
- Gluco/mineralocorticoids, progestogins and derivatives
- Alternative Parents
- 20-oxosteroids / 11-beta-hydroxysteroids / 17-hydroxysteroids / Halogenated steroids / 3-oxo delta-1,4-steroids / Delta-1,4-steroids / Tertiary alcohols / Alpha-hydroxy ketones / Alpha-chloroketones / Secondary alcohols show 7 more
- Substituents
- Progestogin-skeleton / 20-oxosteroid / Hydroxysteroid / Halo-steroid / 9-halo-steroid / Oxosteroid / 11-beta-hydroxysteroid / 11-hydroxysteroid / 3-oxo-delta-1,4-steroid / 3-oxosteroid show 23 more
- Molecular Framework
- Aliphatic homopolycyclic compounds
- External Descriptors
- 11beta-hydroxy steroid, 17alpha-hydroxy steroid, 20-oxo steroid, 3-oxo-Delta(1),Delta(4)-steroid, chlorinated steroid (CHEBI:6970)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Zinc ion binding
- Specific Function
- Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modula...
- Gene Name
- NR3C1
- Uniprot ID
- P04150
- Uniprot Name
- Glucocorticoid receptor
- Molecular Weight
- 85658.57 Da
References
- Isogai M, Shimizu H, Esumi Y, Terasawa T, Okada T, Sugeno K: Binding affinities of mometasone furoate and related compounds including its metabolites for the glucocorticoid receptor of rat skin tissue. J Steroid Biochem Mol Biol. 1993 Feb;44(2):141-5. [PubMed:8439518]
- Lumry WR: A review of the preclinical and clinical data of newer intranasal steroids used in the treatment of allergic rhinitis. J Allergy Clin Immunol. 1999 Oct;104(4 Pt 1):S150-8. [PubMed:10518812]
- Smith CL, Kreutner W: In vitro glucocorticoid receptor binding and transcriptional activation by topically active glucocorticoids. Arzneimittelforschung. 1998 Sep;48(9):956-60. [PubMed:9793625]
- Zhang X, Moilanen E, Adcock IM, Lindsay MA, Kankaanranta H: Divergent effect of mometasone on human eosinophil and neutrophil apoptosis. Life Sci. 2002 Aug 16;71(13):1523-34. [PubMed:12127907]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Agonist
- General Function
- Zinc ion binding
- Specific Function
- The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Progesterone receptor ...
- Gene Name
- PGR
- Uniprot ID
- P06401
- Uniprot Name
- Progesterone receptor
- Molecular Weight
- 98979.96 Da
References
- Madauss KP, Deng SJ, Austin RJ, Lambert MH, McLay I, Pritchard J, Short SA, Stewart EL, Uings IJ, Williams SP: Progesterone receptor ligand binding pocket flexibility: crystal structures of the norethindrone and mometasone furoate complexes. J Med Chem. 2004 Jun 17;47(13):3381-7. [PubMed:15189034]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP2C8
- Uniprot ID
- P10632
- Uniprot Name
- Cytochrome P450 2C8
- Molecular Weight
- 55824.275 Da
References
- Walsky RL, Gaman EA, Obach RS: Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol. 2005 Jan;45(1):68-78. [PubMed:15601807]
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Drug created on June 13, 2005 07:24 / Updated on May 24, 2018 03:41